Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

NCT07285057 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Neoplasms
Prostate Cancer
Prostate Adenocarcinoma

Interventions

RADIATION: rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®)
DRUG: Flotufolastat F18

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]